{
    "clinical_study": {
        "@rank": "42079", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of bryostatin-1 in treating patients with\n      recurrent non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop\n      cancer cells from dividing so they stop growing or die."
        }, 
        "brief_title": "Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma", 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the response to bryostatin 1 (BRYO) administered weekly for 3 weeks in patients\n      with relapsed non-Hodgkin's lymphoma.\n\n      II. Assess the toxic effects of this treatment. III. Establish the correlation between PKC\n      isoenzyme activity and BRYO function in lymphoma cells and normal lymphocytes.\n\n      IV. Determine the pharmacokinetic profile of BRYO and its relationship to pharmacodynamics.\n\n      OUTLINE:\n\n      Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed non-Hodgkin's lymphoma\n\n          -  Working formulation low-, intermediate-, and high-grade histologies eligible\n\n          -  Mantle cell and marginal zone lymphoma eligible\n\n          -  Relapse after at least 1 doxorubicin-containing regimen required\n\n          -  No more than 2 prior chemotherapy regimens\n\n          -  One prior biologic therapy in addition to the 2 prior chemotherapy regimens allowed\n\n          -  No prior bone marrow transplantation\n\n          -  Ineligible for treatment on higher priority protocols\n\n          -  Patients eligible for bone marrow transplantation may be treated to reduce tumor bulk\n\n          -  Bidimensionally measurable disease required\n\n          -  No history of primary or metastatic CNS disease\n\n        PATIENT CHARACTERISTICS:\n\n          -  Age: Any age\n\n          -  Performance status: Zubrod 0-2\n\n          -  Life expectancy: Greater than 12 weeks\n\n          -  Absolute neutrophil count at least 1,000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Bilirubin no greater than 1.8 mg/dL\n\n          -  Transaminases no greater than 2.5 times normal\n\n          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 70 mL/min\n\n          -  No HIV antibody\n\n          -  No serious intercurrent illness\n\n          -  No pregnant or nursing women\n\n          -  Effective contraception required of fertile patients throughout study and for 1 year\n             thereafter\n\n        PRIOR CONCURRENT THERAPY:\n\n        -At least 4 weeks since prior therapy (6 weeks since mitomycin) and recovered"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002725", 
            "org_study_id": "NCI-2012-02239", 
            "secondary_id": [
                "MDA-DM-95061", 
                "NCI-T95-0035D", 
                "CDR0000064591"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "bryostatin 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "chemotherapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bryostatin 1"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent small lymphocytic lymphoma", 
            "recurrent grade 1 follicular lymphoma", 
            "recurrent grade 2 follicular lymphoma", 
            "recurrent grade 3 follicular lymphoma", 
            "recurrent adult diffuse small cleaved cell lymphoma", 
            "recurrent adult diffuse mixed cell lymphoma", 
            "recurrent adult diffuse large cell lymphoma", 
            "recurrent adult immunoblastic large cell lymphoma", 
            "recurrent adult lymphoblastic lymphoma", 
            "recurrent adult Burkitt lymphoma", 
            "recurrent mantle cell lymphoma", 
            "recurrent marginal zone lymphoma", 
            "extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue", 
            "nodal marginal zone B-cell lymphoma", 
            "splenic marginal zone lymphoma"
        ], 
        "lastchanged_date": "February 4, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MDA-DM-95061"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "University of Texas - MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "PHASE II EVALUATION OF BRYOSTATIN-1 (NSC 339555) IN NON-HODGKIN'S LYMPHOMA", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Jorge E. Romaguera, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2000", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002725"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1996", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2000"
    }, 
    "geocoordinates": {
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}